BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9046337)

  • 41. Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.
    Cody V; Galitsky N; Luft JR; Pangborn W; Queener SF; Gangjee A
    Acta Crystallogr D Biol Crystallogr; 2002 Sep; 58(Pt 9):1393-9. PubMed ID: 12198294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
    Gangjee A; Zeng Y; Talreja T; McGuire JJ; Kisliuk RL; Queener SF
    J Med Chem; 2007 Jun; 50(13):3046-53. PubMed ID: 17552508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel non-classical C9-methyl-5-substituted-2,4-diaminopyrrolo[2,3-d]pyrimidines as potential inhibitors of dihydrofolate reductase and as anti-opportunistic agents.
    Gangjee A; Yang J; Queener SF
    Bioorg Med Chem; 2006 Dec; 14(24):8341-51. PubMed ID: 17010625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
    Gangjee A; Mavandadi F; Queener SF; McGuire JJ
    J Med Chem; 1995 Jun; 38(12):2158-65. PubMed ID: 7783147
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
    Gangjee A; Namjoshi OA; Raghavan S; Queener SF; Kisliuk RL; Cody V
    J Med Chem; 2013 Jun; 56(11):4422-41. PubMed ID: 23627352
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
    Gangjee A; Jain HD; Queener SF; Kisliuk RL
    J Med Chem; 2008 Aug; 51(15):4589-600. PubMed ID: 18605720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-activity correlations for three pyrido[2,3-d]pyrimidine antifolates binding to human and Pneumocystis carinii dihydrofolate reductase.
    Cody V; Pace J; Namjoshi OA; Gangjee A
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):799-803. PubMed ID: 26057816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
    Cody V; Pace J; Chisum K; Rosowsky A
    Proteins; 2006 Dec; 65(4):959-69. PubMed ID: 17019704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
    Gangjee A; Adair OO; Pagley M; Queener SF
    J Med Chem; 2008 Oct; 51(19):6195-200. PubMed ID: 18771252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of three crystal structure determinations of a 5-methyl-6-N-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase.
    Cody V; Luft JR; Pangborn W; Gangjee A
    Acta Crystallogr D Biol Crystallogr; 2003 Sep; 59(Pt 9):1603-9. PubMed ID: 12925791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.
    Bartlett MS; Shaw M; Navaran P; Smith JW; Queener SF
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2436-41. PubMed ID: 8585722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens.
    Bag S; Tawari NR; Degani MS; Queener SF
    Bioorg Med Chem; 2010 May; 18(9):3187-97. PubMed ID: 20363634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
    Stevens MF; Phillip KS; Rathbone DL; O'Shea DM; Queener SF; Schwalbe CH; Lambert PA
    J Med Chem; 1997 Jun; 40(12):1886-93. PubMed ID: 9191966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates.
    Gangjee A; Yang J; McGuire JJ; Kisliuk RL
    Bioorg Med Chem; 2006 Dec; 14(24):8590-8. PubMed ID: 16990006
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
    Rosowsky A; Mota CE; Queener SF; Waltham M; Ercikan-Abali E; Bertino JR
    J Med Chem; 1995 Mar; 38(5):745-52. PubMed ID: 7877140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
    Graffner-Nordberg M; Kolmodin K; Aqvist J; Queener SF; Hallberg A
    J Med Chem; 2001 Jul; 44(15):2391-402. PubMed ID: 11448221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry.
    Cody V; Luft JR; Pangborn W; Gangjee A; Queener SF
    Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):646-55. PubMed ID: 15039552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate reductase.
    Gangjee A; Lin X
    J Med Chem; 2005 Mar; 48(5):1448-69. PubMed ID: 15743188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.
    Li H; Fang F; Liu Y; Xue L; Wang M; Guo Y; Wang X; Tian C; Liu J; Zhang Z
    Bioorg Med Chem; 2018 May; 26(9):2674-2685. PubMed ID: 29691154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.
    Nelson RG; Rosowsky A
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3293-303. PubMed ID: 11709300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.